Key Takeaway: Werewolf Therapeutics, Inc. reported its financial results for the third quarter of 2024. The company also provided a business update, although specific details regarding financial performance or strategic initiatives were not included in the article. The announcement was made on November 7, 2024, from Watertown, Massachusetts.
Price reaction · baseline $2.44 (2024-11-06 close) · hit pre-market · 1 other HOWL headline(s) in the window, move may be shared
day 0 close
-8.2%
day 1
-5.7%
day 3 · peak
-11.9%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
November 7, 2024
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
WATERTOWN, Mass., November 7, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)